Pharmaceutical Executive-09-01-2020

From the Editor

September 16, 2020

In this September 2020 Product Launch issue of Pharm Exec, we highlight five products, all approved in 2019, and showcase what is now their early brand journey.

Features

September 14, 2020

Beyond necessity and nice-to-have, embracing real-world evidence as a true strategic differentiator.

Features

September 14, 2020

Turning to a next-gen psoriasis treatment to help drive future fortunes.

While COVID-19 has shifted some of the rules, research reveals that practice changes were already afoot for market newcomers.

Features

September 14, 2020

Uncovering fish oil derivative’s benefit for heart health.

Features

September 14, 2020

New hope accompanies overdue recognition in sickle cell disease fight.

Features

September 14, 2020

Addressing the need for fast-acting therapy in treatment-resistant depression.

Features

September 14, 2020

The world’s most expensive drug put in context.

The key factors behind the sector’s strong surge in new equity fundraisings.

Orphan drug incentives set to remain in place in Europe.

Tasked with setting up framework for essential medicine program.

How adoption of the key account management (KAM) model can help drive pharma’s agility in reaching and influencing a more diverse set of healthcare customers and decision-makers.

Columns

September 11, 2020

As we wait for a COVID-19 vaccine, pharma is looking to blockchain technology to prepare for the major supply-chain obstacles to come.

Columns

September 11, 2020

Creating behavioral change in the pharma workplace.

Features

September 11, 2020

Amid pandemic, rely on the fundamentals.

Features

September 11, 2020

A glimpse inside the latest turn in Liz Barrett’s influential journey as an oncology executive—this time leaving the confines of big pharma to tackle the innovation void in treating urologic cancers.

Columns

September 11, 2020

ESG objectives are integral to long-term biopharma strategy.

Assessing COVID-19’s wide and varied impact on pharma and biotech business in the first half of the year, and how it shapes market prospects ahead.

Click the title above for a link to open the Pharmaceutical Executive September 2020 issue in an interactive PDF format.